跳至主要内容
临床试验/NCT03172195
NCT03172195终止不适用

Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up

Centre Hospitalier Universitaire de Saint Etienne1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2017年10月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
80
试验地点
1
主要终点
Number of patients with different viral load in the colonic mucosa

研究概览

简要总结

Flare-up of ulcerative colitis (UC) is characterized by the inflammation of colon mucosa that requires the use of immunosuppressive therapies. In previous studies, the active role of cytomegalovirus (CMV) has been demonstrated, with a correlation between the cytomegalovirus DNA ((deoxyribonucleic acid) load in the inflamed tissue and the resistance to successive lines of immunosuppressive therapy (Roblin et al., Am J Gastroenterol 2011). The main aim of this monocentric prospective study is to evaluate the DNA viral load by qPCR (Polymerase Chain Reaction) of 3 herpesviruses (Epstein-Barr virus, herpes virus 6 and herpes simplex) together with that of CMV in colonic mucosa depending of the local inflammation (endoscopically normal region, inflamed mucosa or ulcer) in patients suffering of moderate to severe UC flare-up (Mayo score >6 with endoscopic score higher or equal than 2). The viral load will also be correlated to the Mayo endoscopic score and the response to immunosuppressive drugs (steroid and anti-TNF (Tumor Necrosis Factor) monoclonal antibodies).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age>18 years
  • Voluntary to participate to the study
  • Flare-up of ulcerative colitis with Mayo score >6
  • Ability to receive steroid or anti-TNF therapy
  • Agree the rectosigmoidoscopy and the therapies

排除标准

  • Age <18 years
  • Pregnancy
  • Disagree the rectosigmoidoscopy or the therapies
  • Participation to the evaluation of a new therapy
  • Colectomy (partial or total)
  • Contraindication of steroid or anti-TNF therapy
  • Anticoagulant drugs

研究组 & 干预措施

Patients with ulcerative colitis

Experimental

Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.

干预措施: rectosigmoidoscopy (Procedure)

Patients with ulcerative colitis

Experimental

Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.

干预措施: biopsies (Biological)

Patients with ulcerative colitis

Experimental

Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.

干预措施: blood sample (Biological)

结局指标

主要结局

Number of patients with different viral load in the colonic mucosa

时间窗: day 1

Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV. It will be measured by Polymerase Chain Reaction technical in colonic mucosa

次要结局

  • Correlation of the different viral loads with the steroid treatment response(up to 24 months)
  • Correlation of the different viral loads with the anti-TNF treatment response(up to 24 months)
  • Correlation of the different viral loads with the Mayo endoscopic score(Day 1)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and... | 临床试验